Workflow
Brookfield Business Partners L.P.(BBU) - 2025 Q1 - Earnings Call Transcript

Financial Data and Key Metrics Changes - First quarter adjusted EBITDA was $591 million, an increase from $544 million in the prior period [18] - Adjusted EFO for the quarter was $345 million, which included a $114 million net gain from the sale of an offshore oil services operation [18] - The company ended the quarter with liquidity of approximately CAD 2.3 billion at the corporate level [20] Business Line Data and Key Metrics Changes - The Industrial segment generated adjusted EBITDA of $304 million, benefiting from tax benefits and contributions from a newly acquired electric heat tracing manufacturer [18] - The Business Service segment's adjusted EBITDA was CAD 213 million, an increase from CAD 205 million in 2024, driven by strong performance in residential mortgage insurance and improved project execution [19] - The Infrastructure Services segment's adjusted EBITDA was $104 million, down from $143 million in the same quarter last year, impacted by weak market conditions in work access services [20] Market Data and Key Metrics Changes - The U.S. remains an attractive destination for capital, with ongoing investments in the backbone of the economy [7] - Growth in Europe has lagged behind the U.S., but there are signs of a pro-growth agenda from governments [8] - India and the Gulf countries are highlighted as bright spots in the global economy, providing a conducive deal-making environment [8] Company Strategy and Development Direction - The company aims to own market-leading businesses and enhance their performance and cash flows, focusing on capital recycling initiatives and strategic acquisitions [5][6] - The strategy includes adapting to economic cycles and leveraging operational capabilities to create value [6][10] - The company is exploring opportunities in digitalization and relocalization as key growth themes [6][8] Management's Comments on Operating Environment and Future Outlook - Management acknowledges potential impacts from tariffs and global economic growth but remains confident in the resilience of their businesses [12][16] - The company is preparing for a more uncertain outlook over the next 12 to 18 months, focusing on operational capabilities and cost optimization [16][17] - Management believes that the long-term impacts of U.S. trade policy could be positive for their businesses [16] Other Important Information - The company has initiated a $250 million share repurchase program, returning $140 million to shareholders so far [5][21] - The acquisition of Antilia Scientific is expected to enhance the company's manufacturing and commercial strategy [9] Q&A Session Summary Question: Impact of tariffs on Dexco's EBITDA - Management indicated that while there are signs of recovery in North America, the market remains muted, and they are managing costs effectively to improve margins [25][26] Question: Status of Clarios' tax filing - Management confirmed that the tax return for 2024 is being processed normally, and they expect to receive tax benefits soon [27][28] Question: Plans for returning capital to shareholders - Management stated they are always looking for monetization opportunities and would consider expanding the share buyback program if further realizations occur [29][30] Question: Realignment at Scientific Games - Management highlighted significant opportunities in digitizing the lottery ecosystem and has appointed a new head of digital to drive this initiative [35][36] Question: Participation in Barclays payments business - Management confirmed participation in the Barclays investment, aligning with their strategy in financial infrastructure [37][38] Question: Performance of Unidos in Brazil - Management reported stable performance in fleet management and car rental, with positive cash flow despite rising interest rates [49][52] Question: Actions to manage tariff impacts - Management is actively implementing pricing actions and cost optimization initiatives to mitigate tariff impacts, particularly in Clarios and Dexco [56][57]